Work in transgenic tauopathy mouse models has shown that microglia drive tau pathology and tau-mediated neurodegeneration [53] and that tau pathology drives an activated microglial response [54] through cyclic GMP-AMP synthase and interferon signaling [55]. The gene discussed is MAPT; the disease is tauopathy.